BeOne Medicines (BEIGF) Short-term Investments (2015 - 2023)

BeOne Medicines (BEIGF) has 9 years of Short-term Investments data on file, last reported at $2.6 million in Q4 2023.

• Short-term Investments for Q4 2023 came in at $2.6 million, down 99.61% year-over-year; the trailing twelve-month figure through Dec 2023 was $2.6 million (down 99.61% YoY), and the FY2023 annual result was $2.6 million, down 99.61% from the prior year.
• Short-term Investments declined to $2.6 million in Q4 2023 per BEIGF's latest filing, from $107.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $3.3 billion in Q4 2020 and troughed at $2.6 million in Q4 2023.
• A 5-year average of $1.4 billion and a median of $1.0 billion in 2022 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2020 and 2023: Short-term Investments soared 796.21% in 2020, then tumbled 99.61% in 2023.
• A 5-year view of Short-term Investments shows it stood at $364.7 million in 2019, then soared by 796.21% to $3.3 billion in 2020, then plunged by 31.41% to $2.2 billion in 2021, then slumped by 70.33% to $665.3 million in 2022, then plunged by 99.61% to $2.6 million in 2023.
• Business Quant data shows BEIGF's Short-term Investments at $2.6 million in Q4 2023, $107.0 million in Q3 2023, and $105.7 million in Q2 2023.